Is Mural Oncology Stock a Good Investment?
Mural Oncology Investment Advice | MURA |
- Examine Mural Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Mural Oncology's leadership team and their track record. Good management can help Mural Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Mural Oncology's business and its evolving consumer preferences.
- Compare Mural Oncology's performance and market position to its competitors. Analyze how Mural Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Mural Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Mural Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Mural Oncology plc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Mural Oncology plc is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Mural Oncology Stock
Researching Mural Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 69.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.36. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mural Oncology plc recorded a loss per share of 9.03. The entity had not issued any dividends in recent years.
To determine if Mural Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mural Oncology's research are outlined below:
| Mural Oncology plc had very high historical volatility over the last 90 days | |
| Mural Oncology plc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (207.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mural Oncology generates negative cash flow from operations | |
| Mural Oncology plc has a frail financial position based on the latest SEC disclosures | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Mural Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mural Oncology plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mural Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Mural Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Mural Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -2.66 | -1.84 | 0.82 | 30 |
Mural Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.1 M.Market Cap |
|
Mural Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (0.71) | (0.75) | |
| Return On Assets | (0.69) | (0.72) | |
| Return On Equity | (0.79) | (0.75) |
Determining Mural Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Mural Oncology is a good buy. For example, gross profit margin measures Mural Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mural Oncology's profitability and make more informed investment decisions.
Please note, the presentation of Mural Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mural Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mural Oncology's management manipulating its earnings.
Basic technical analysis of Mural Stock
As of the 17th of December 2024, Mural Oncology secures the Risk Adjusted Performance of 0.034, downside deviation of 2.59, and Mean Deviation of 2.16. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mural Oncology plc, as well as the relationship between them.Mural Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mural Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mural Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mural Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Goodman Vicki L over a month ago Disposition of 5069 shares by Goodman Vicki L of Mural Oncology at 3.33 subject to Rule 16b-3 | ||
Minegishi Sachiyo over two months ago Insider Trading | ||
Altschuller Susan over three months ago Acquisition by Altschuller Susan of 10000 shares of Mural Oncology at 3.2071 subject to Rule 16b-3 | ||
Golumbeski George over three months ago Insider Trading | ||
Keson-brookes Maiken over three months ago Disposition of 2157 shares by Keson-brookes Maiken of Mural Oncology at 3.41 subject to Rule 16b-3 | ||
Caroline Loew over three months ago Disposition of 12531 shares by Caroline Loew of Mural Oncology at 2.91 subject to Rule 16b-3 | ||
Hickey Benjamin over six months ago Acquisition by Hickey Benjamin of 15021 shares of Mural Oncology at 3.61 subject to Rule 16b-3 | ||
Jackson Scott Thomas over six months ago Insider Trading | ||
Cafico Trust Co Ltd over a year ago Mural Oncology exotic insider transaction detected |
Mural Oncology's Outstanding Corporate Bonds
Mural Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mural Oncology plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mural bonds can be classified according to their maturity, which is the date when Mural Oncology plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Mural Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Mural Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.034 | |||
| Market Risk Adjusted Performance | 0.1267 | |||
| Mean Deviation | 2.16 | |||
| Semi Deviation | 2.35 | |||
| Downside Deviation | 2.59 | |||
| Coefficient Of Variation | 2749.73 | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.15 | |||
| Information Ratio | 0.0096 | |||
| Jensen Alpha | 0.0375 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0118 | |||
| Treynor Ratio | 0.1167 | |||
| Maximum Drawdown | 20.93 | |||
| Value At Risk | (5.22) | |||
| Potential Upside | 4.76 | |||
| Downside Variance | 6.73 | |||
| Semi Variance | 5.52 | |||
| Expected Short fall | (2.66) | |||
| Skewness | 1.8 | |||
| Kurtosis | 7.68 |
| Risk Adjusted Performance | 0.034 | |||
| Market Risk Adjusted Performance | 0.1267 | |||
| Mean Deviation | 2.16 | |||
| Semi Deviation | 2.35 | |||
| Downside Deviation | 2.59 | |||
| Coefficient Of Variation | 2749.73 | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.15 | |||
| Information Ratio | 0.0096 | |||
| Jensen Alpha | 0.0375 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0118 | |||
| Treynor Ratio | 0.1167 | |||
| Maximum Drawdown | 20.93 | |||
| Value At Risk | (5.22) | |||
| Potential Upside | 4.76 | |||
| Downside Variance | 6.73 | |||
| Semi Variance | 5.52 | |||
| Expected Short fall | (2.66) | |||
| Skewness | 1.8 | |||
| Kurtosis | 7.68 |
Consider Mural Oncology's intraday indicators
Mural Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mural Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 15487.56 | |||
| Daily Balance Of Power | (0.53) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 3.6 | |||
| Day Typical Price | 3.55 | |||
| Price Action Indicator | (0.26) | |||
| Period Momentum Indicator | (0.20) |
Mural Oncology Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Mural Stock media impact
Far too much social signal, news, headlines, and media speculation about Mural Oncology that are available to investors today. That information is available publicly through Mural media outlets and privately through word of mouth or via Mural internal channels. However, regardless of the origin, that massive amount of Mural data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mural Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mural Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mural Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mural Oncology alpha.
Mural Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Mural Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mural Oncology Corporate Executives
Elected by the shareholders, the Mural Oncology's board of directors comprises two types of representatives: Mural Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mural. The board's role is to monitor Mural Oncology's management team and ensure that shareholders' interests are well served. Mural Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mural Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mural Oncology plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.03) | Return On Assets (0.81) | Return On Equity (1.78) |
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Mural Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.